Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Jie Sun,Hua Meng,Lu Yao,Meng Lv,Jian Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1158/1078-0432.22463223.v1

2023-01-01

Abstract:Two Germline Pathogenic Mutations

What problem does this paper attempt to address?

Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Jie Sun,Hua Meng,Lu Yao,Meng Lv,Jian Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1158/1078-0432.22463223

2023-01-01

Abstract:Two Germline Pathogenic Mutations
Table S1 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Jun Sun,Hua Meng,Yao Lu,Meng Lv,Jing Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Y. G. Xie

DOI: https://doi.org/10.1158/1078-0432.22463232.v1

2023-01-01

Abstract:Categories of the 46 Cancer Susceptibility Genes
Table S6 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Jie Sun,Hua Meng,Lu Yao,Meng Lv,Jian Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1158/1078-0432.22463217.v1

2023-01-01

Abstract:Univariate Analyses of Disease-free Survival and Disease-specific Survival
Table S8 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Jun Sun,Hua Meng,Yao Lu,Meng Lv,Jing Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Y. G. Xie

DOI: https://doi.org/10.1158/1078-0432.22463211.v1

2023-01-01

Abstract:Survival in Molecular Subgroups
Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Jie Sun,Hua Meng,Lu Yao,Meng Lv,Jian Bai,Jianguang Zhang,Lientu Wang,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Yuntao Xie

DOI: https://doi.org/10.1158/1078-0432.ccr-16-3227

IF: 13.801

2017-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: The prevalence of mutations in cancer susceptibility genes such as BRCA1 and BRCA2 and other cancer susceptibility genes and their clinical relevance are largely unknown among a large series of unselected breast cancer patients in the Chinese population. Experimental Design: A total of 8,085 consecutive unselected Chinese breast cancer patients were enrolled. Germline mutations in 46 cancer susceptibility genes were detected using a 62-gene panel. Results: Pathogenic mutations were identified in 9.2% of patients among the 8,085 unselected breast cancer patients. Of these, 5.3% of patients carried a BRCA1 or BRCA2 mutation (1.8% in BRCA1 and 3.5% in BRCA2), 2.9% carried other breast cancer susceptibility genes (BOCG) and 1.0% carried another cancer susceptibility genes. Triple-negative breast cancers had the highest prevalence of BRCA1/2 mutations (11.2%) and other BOCG mutations (3.8%) among the four molecular subgroups, whereas ER−/PR−HER2+ breast cancers had the lowest mutations in BRCA1/2 (1.8%) and BOCG (1.6%). In addition, BRCA1 mutation carriers had a significant worse disease-free survival [unadjusted hazard ratio (HR) 1.60; 95% confidence interval (CI) 1.10–2.34; P = 0.014] and disease-specific survival (unadjusted HR 1.96; 95% CI, 1.03–3.65; P = 0.040) than did non-carriers, whereas no significant difference in survival was found between BRCA2 mutation carriers and non-carriers. Conclusions: 9.2% of breast cancer patients carry a pathogenic mutation in cancer susceptibility genes in this large unselected series. Triple-negative breast cancers have the highest prevalence of mutations in BRCA1 /2 and other breast cancer susceptibility genes among the four molecular subgroups, whereas ER−/PR−HER2+ breast cancers had the lowest mutations in these genes. Clin Cancer Res; 23(20); 6113–9. ©2017 AACR.
Supplementary Table S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Haoran Wang,Yuping Chen,Xinshu Wang,Binhao Huang,Juntao Xie,Hui Yin,Jie Yang,Jinhuan Wu,Jian Yuan,Jie Zhang

DOI: https://doi.org/10.1158/1078-0432.25603569.v1

2024-01-01

Abstract:Supplementary Table S1: The gene list for pathway enrichment analysis.
Table S9 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in brca1 Mutation Carriers

Hu Li,Li‐Ming Su,Hainan Cheng,Chunling Mo,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Jianguang Zhang,Yuntao Xie

DOI: https://doi.org/10.1158/0008-5472.22429011.v1

2023-01-01

Abstract:Table S9. Oncogenic mutations detected in the breast tumor tissues from four BRCA1 mutation carriers.
Table ST3 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Jintao Guo,Ying Zhou,Chaoqun Xu,Qinwei Chen,Zsófia Sztupinszki,Judit Börcsök,Canqiang Xu,Feng Ye,Weiwei Tang,Jiapeng Kang,Lu Yang,Jiaxin Zhong,Taoling Zhong,Tianhui Hu,Rongshan Yu,Zoltan Szallasi,Xianming Deng,Qiyuan Li

DOI: https://doi.org/10.1158/0008-5472.22361530.v1

2023-01-01

Abstract:The clinical information of 60 LUAD patients which received chemotherapy and target therapies.
Table ST1 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Jintao Guo,Ying Zhou,Chaoqun Xu,Qinwei Chen,Zsófia Sztupinszki,Judit Börcsök,Canqiang Xu,Feng Ye,Weiwei Tang,Jiapeng Kang,Lu Yang,Jiaxin Zhong,Taoling Zhong,Tianhui Hu,Rongshan Yu,Zoltan Szallasi,Xianming Deng,Qiyuan Li

DOI: https://doi.org/10.1158/0008-5472.22361536.v1

2023-01-01

Abstract:The mutational propensities and PCA results of each patients.
Supplementary Table S9 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515841

2024-01-01

Abstract:Table S9.The frequency data of rs3744797.
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Jiayu Wang,Weiwei Li,Yujian Shi,Yan Huang,Tao Sun,Lili Tang,Qing Lu,Qiumo Lei,Ning Liao,Feng Jin,Hui Li,Tao Huang,Jun Qian,Danmei Pang,Shusen Wang,Peizhi Fan,Xinhong Wu,Ying Lin,Haiyan Qin,Binghe Xu

DOI: https://doi.org/10.1002/cam4.2093

IF: 4.711

2019-01-01

Cancer Medicine

Abstract:Genetic testing for germline mutations in BRCA1/2 of patients with breast cancer (BC) is part of routine patient care. However, BRCA1/2 mutations account only for a fraction of familial BC. A custom panel of 22 gene sequencing was performed on each patient. Among the 481 female patients, 135 patients were detected to carry pathogenic (P)/likely pathogenic (LP) mutations (28.1%), which corresponded to 12 different cancer predisposition genes [14.6% (70/481) on BRCA1 gene, 5.0% (24/481) on BRCA2 gene, 8.5% (41/481) on non-BRCA1/2 genes]. Moreover, 24.7% (119/481) of patients had mutation of unknown significance (VUS) in these genes. The most common (8/481) pathogenic mutation is BRCA1 c.5470_5477del, while BRIP1 2392 C > T of patients was detected. All the mutations detected were mainly seen in the homologous recombinant repair pathway. Compared to BRCA2 mutation, BRCA1 mutation is higher in younger female patients (P < 0.01). Some pathogenic mutations were detected in the patients' familiy members without the past history of tumor and 92 novel mutations were detected (31 on BRCA including 2 P, 16 LP, 13 VUS; 61 on non-BRCA1/2 including 9 LP, 52 VUS). The detection rate of BRCA1/2 mutations was higher in patients with three or more cancer family members than those with one or two. However, the difference was not statistically different. The results suggest that multigene panel testing can increase mutation detection rate for high-risk BC patients. Detailed family history can help to categorize new mutations.
Supplementary Table S5 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515853.v1

2024-01-01

Abstract:Table S5.Candidate genes and SNPs.
Table S1-S7 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers

Li Hu,Liming Su,Hainan Cheng,Chunling Mo,Tao Ouyang,Jinfeng Li,Tianfeng Wang,Zhaoqing Fan,Tie Fan,Benyao Lin,Jianguang Zhang,Yuntao Xie

DOI: https://doi.org/10.1158/0008-5472.22429017

2023-01-01

Abstract:Table S1. Detailed information on the BRCA1 germline mutation and clinicopathological characteristics of seven patients; Table S2. Cell numbers detected by single cell RNA-seq; Table S3. List of cell type specific marker genes identified at a single cell resolution; Table S4. EMT signature gene set; Table S5. Clinicopathologic information of 8 additional BRCA1 mutation carriers and 14 non-carriers for bulk RNA-seq; Table S6. Clinico-pathologic information of the breast cancers from BRCA1/2 germline mutation carriers from The Cancer Genome Atlas (TCGA) database included in this study for comparisons; Table S7. Clinicopathologic information of 7 BRCA1 mutation carriers and 10 non-carriers whose samples for immunohistochemistry staining.
Germline Mutations in 32 Cancer Susceptibility Genes by Next-Generation Sequencing among Breast Cancer Patients

Yu Yang,Chang Liu,Zhong-ling Zhuo,Fei Xie,Ke Wang,Shu Wang,Xiao-tao Zhao

DOI: https://doi.org/10.1159/000532095

2024-01-01

Oncology

Abstract:Introduction: BRCA1/2 germline mutations are the most well-known genetic determinants for breast cancer. However, the distribution of germline mutations in non-BRCA1/2 cancer susceptibility genes in Chinese breast cancer patients is unclear. The association between clinical characteristics and germline mutations remains to be explored.Methods: Consecutive breast cancer patients from Peking University People's Hospital were enrolled. Clinical characteristics were collected and next-generation sequencing (NGS) was performed using blood samples of participants to identify pathogenic/likely pathogenic (P/LP) germline mutations in 32 cancer susceptibility genes including homologous recombination repair (HRR) genes.Results: A total of 885 breast cancer patients underwent the detection of germline mutations. 107 P/LP germline mutations of 17 genes were identified in 116 breast cancer patients including 79 (8.9%) in BRCA1/2 and 40 (4.5%) in 15 non-BRCA1/2 genes. PALB2 was the most frequently mutated gene other than BRCA1/2 but still relatively rare (1.1%). There were 38 novel P/LP germline variants detected. P/LP germline mutations in BRCA1/2 were significantly associated with onset age(P<0.001), the family history of breast/ovarian cancer(P=0.010), and molecular subtype(P<0.001), while correlated with onset age (P<0.001), site of breast tumor (P=0.028) and molecular subtype (P< 0.001) in HRR genes.Conclusions: The multiple-gene panel prominently increased the detection rate of P/LP germline mutations in 32 cancer susceptibility genes compared to BRCA1/2 alone. Onset younger than or equal to 45 years of age, bilateral and triple-negative breast cancer (TNBC) patients may be more likely to be recommended for detecting P/LP germline mutations in HRR genes.
Germline Mutations in 40 Cancer Susceptibility Genes among Chinese Patients with High Hereditary Risk Breast Cancer

Jun-Yan Li,Ruilin Jing,Hongyi Wei,Minghao Wang,Qi Xiaowei,Haoxi Liu,Liu Jian,Jiang-Hua Ou,Wei-Hua Jiang,Fu-Guo Tian,Yuan Sheng,Heng-Yu Li,Hong Xu,Rui-Shan Zhang,Ai-Hua Guan,Ke Liu,Hong-Chuan Jiang,Yu Ren,Jian-Jun He,Weiwei Huang,Ning Liao,Xiangjun Cai,Jia Ming,Rui Ling,Yan Xu,Chun-Yan Hu,Jianguo Zhang,Baoliang Guo,Lizhi Ouyang,Ping Shuai,Zhenzhen Liu,Ling Zhong,Zhen Zeng,Ting Zhang,Zhaoling Xuan,Xuanni Tan,Junbin Liang,Qinwen Pan,Li Chen,Fan Zhang,Lin-Jun Fan,Yi Zhang,Xinhua Yang,Jing BoLi,Chongjian Chen,Jun Jiang

DOI: https://doi.org/10.1002/ijc.31601

2018-01-01

International Journal of Cancer

Abstract:Multigene panel testing of breast cancer predisposition genes have been extensively conducted in Europe and America, which is relatively rare in Asia however. In this study, we assessed the frequency of germline mutations in 40 cancer predisposition genes, including BRCA1 and BRCA2, among a large cohort of Chinese patients with high hereditary risk of BC. From 2015 to 2016, consecutive BC patients from 26 centers of China with high hereditary risk were recruited (n = 937). Clinical information was collected and next-generation sequencing (NGS) was performed using blood samples of participants to identify germline mutations. In total, we acquired 223 patients with putative germline mutations, including 159 in BRCA1/2, 61 in 15 other BC susceptibility genes and 3 in both BRCA1/2 and non-BRCA1/2 gene. Major mutant non-BRCA1/2 genes were TP53 (n = 18), PALB2 (n = 11), CHEK2 (n = 6), ATM (n = 6) and BARD1 (n = 5). No factors predicted pathologic mutations in non-BRCA1/2 genes when treated as a whole. TP53 mutations were associated with HER-2 positive BC and younger age at diagnosis; and CHEK2 and PALB2 mutations were enriched in patients with luminal BC. Among high hereditary risk Chinese BC patients, 23.8% contained germline mutations, including 6.8% in non-BRCA1/2 genes. TP53 and PALB2 had a relatively high mutation rate (1.9 and 1.2%). Although no factors predicted for detrimental mutations in non-BRCA1/2 genes, some clinical features were associated with mutations of several particular genes.
Supplementary Table S6 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515850

2024-01-01

Abstract:Table S6. Log-rank analysis in candidate SNPs.
Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Nan Wang,Jiayang Zhang,Lu Tan,Hao Liao,Yaxin Liu,Xinyu Gui,Jiaxin Niu,Feng Xie,Yue Zhang,Yong Huang,Jianjun Yu,Huiping Li

DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps16-08

IF: 11.2

2021-01-01

Cancer Research

Abstract:Abstract Background: Genetic testing for patients with breast cancer (BCa) patients may change the routine patient care and shift the paradigm towards more personalized managing and treatment strategies. In particular, testing germline mutations in BRCA1/2 has become a part of the standard clinical practice for patients with BCa. However, our understanding of genetic epidemiology of BCa is mainly driven by data from Caucasian populations and it has been evident that gene alterations may be ethnic specific in breast cancer. Methods: Aiming to delineate the landscape of germline mutations in Chinese patients with BCa to breast cancer, we collected blood samples from in 356 BCa patients at stage I-IV in Beijing Cancer Hospital between Jan. 2013 to Dec. 2019. Peripheral blood mononuclear cells were isolated from blood samples and genomic DNA were extracted for capture-based NGS sequencing. A large comprehensive 600 gene panel (PredicineATLAS, Huidu Medical Science Techonology, Inc.) was used to detect germline mutations in the covered genes with average 300x sequencing depth. Results: A total of 356 BCa patients were included in our study, with the median age at first diagnosis of 49 years (Range: 21-87). Among all cases, 21.9% (78/356, 95% confidence interval [CI]: 17.7-26.6%) carried pathogenic or likely pathogenic mutations in 48 cancer related genes. Twenty-seven patients (7.6%, 95% CI: 5.1-10.8%) harbored BRCA1/2 mutations, followed by 5 patients carrying ATM mutations and RAD50 mutations respectively. Other commonly mutated genes include BARD1 (1.1%), FANCD2 (1.1%), CHEK2 (0.6%), FANCC (0.6%), FANCM (0.6%), PMS2 (0.6%), and TP53 (0.6%), most of which are related to DNA damage repair pathway. Moreover, BRCA1/2 carriers were more likely to appear among those with breast or ovarian cancer family history than those without (OR=3.41, 95% CI: 1.14-9.12, P=0.01). Compared with patients that aged older than 50 years at first diagnosis, those aged 30 years or younger were 6 times more likely to detect germline mutations in BRCA1/2 (95% CI: 1.18-26.1, P=0.02). In addition, mutations in BRCA1/2 were differentially associated with breast cancer subtypes. BRCA1 mutations were strongly enriched in triple-negative breast cancer (TNBC) (OR=6.7, 95% CI: 1.54-33.13, P=0.005). There is no strong significant survival difference observed between BRCA1/2 carriers and non-carriers, however, patients carrying ATM or RAD50 mutations tend to have lower disease-free survival. Conclusions: This is a comprehensive analysis of germline mutation spectrum in a large Chinese patient cohort with breast cancer. Collectively, a substantial proportion of patients with breast cancer had hereditary risk factors. Distinct distribution of pathogenic mutations in breast cancer subtypes and differential associations between mutation status and clinical features were further observed. All these findings will advance our understanding regarding the pathologies and heterogeneity of breast cancer. Citation Format: Nan Wang, Jiayang Zhang, Lu Tan, Hao Liao, Yaxin Liu, Xinyu Gui, Jiaxin Niu, Feng Xie, Yue Zhang, Yong Huang, Jianjun Yu, Huiping Li. Germline mutation landscape in Chinese breast cancer patients [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS16-08.
Supp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Catherine S. Grasso,Marios Giannakis,Daniel K. Wells,Tsuyoshi Hamada,Xinmeng Jasmine Mu,Michael Quist,Jonathan A. Nowak,Reiko Nishihara,Zhi Rong Qian,Kentaro Inamura,Teppei Morikawa,Katsuhiko Nosho,Gabriel Abril-Rodriguez,Charles Connolly,Helena Escuin-Ordinas,Milan S. Geybels,William M. Grady,Li Hsu,Siwen Hu-Lieskovan,Jeroen R. Huyghe,Yeon Joo Kim,Paige Krystofinski,Mark D.M. Leiserson,Dennis J. Montoya,Brian B. Nadel,Matteo Pellegrini,Colin C. Pritchard,Cristina Puig-Saus,Elleanor H. Quist,Ben J. Raphael,Stephen J. Salipante,Daniel Sanghoon Shin,Eve Shinbrot,Brian Shirts,Sachet Shukla,Janet L. Stanford,Wei Sun,Jennifer Tsoi,Alexander Upfill-Brown,David A. Wheeler,Catherine J. Wu,Ming Yu,Syed H. Zaidi,Jesse M. Zaretsky,Stacey B. Gabriel,Eric S. Lander,Levi A. Garraway,Thomas J. Hudson,Charles S. Fuchs,Antoni Ribas,Shuji Ogino,Ulrike Peters

DOI: https://doi.org/10.1158/2159-8290.22532711

2023-01-01

Abstract:Supplementary Table S2: Somatic mutations
Table ST2 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Jintao Guo,Ying Zhou,Chaoqun Xu,Qinwei Chen,Zsófia Sztupinszki,Judit Börcsök,Canqiang Xu,Feng Ye,Weiwei Tang,Jiapeng Kang,Lu Yang,Jiaxin Zhong,Taoling Zhong,Tianhui Hu,Rongshan Yu,Zoltan Szallasi,Xianming Deng,Qiyuan Li

DOI: https://doi.org/10.1158/0008-5472.22361533.v1

2023-01-01

Abstract:The genetic determinants of the mutational propensities. A) The integrated regression results of 2,314 unique candidate genes. B) The instrumental variable regression results of 485 unique E-genes. C) The instrumental variable regression results of 1,427 unique I-genes. D) The overlapped genes between E-genes and I-genes.
Supplementary Table S1 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515865.v1

2024-01-01

Abstract:Table S1. Patients’ characteristics.

Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S1 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S6 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S8 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Supplementary Table S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Table S9 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in <i>brca1</i> Mutation Carriers

Table ST3 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Table ST1 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Supplementary Table S9 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Supplementary Table S5 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Table S1-S7 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers

Germline Mutations in 32 Cancer Susceptibility Genes by Next-Generation Sequencing among Breast Cancer Patients

Germline Mutations in 40 Cancer Susceptibility Genes among Chinese Patients with High Hereditary Risk Breast Cancer

Supplementary Table S6 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Supp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Table ST2 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Supplementary Table S1 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S4 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S1 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S6 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Table S8 from Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients

Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.

Supplementary Table S1 from Germline Mutations of Holliday Junction Resolvase Genes in Multiple Primary Malignancies Involving Lung Cancer Lead to PARP Inhibitor Sensitization

Table S9 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in &lt;i&gt;brca1&lt;/i&gt; Mutation Carriers

Table ST3 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Table ST1 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Supplementary Table S9 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes.

Supplementary Table S5 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Table S1-S7 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in BRCA1 Mutation Carriers

Germline Mutations in 32 Cancer Susceptibility Genes by Next-Generation Sequencing among Breast Cancer Patients

Germline Mutations in 40 Cancer Susceptibility Genes among Chinese Patients with High Hereditary Risk Breast Cancer

Supplementary Table S6 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Abstract PS16-08: Germline Mutation Landscape in Chinese Breast Cancer Patients

Supp. Table S2 from Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Table ST2 from Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Supplementary Table S1 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Table S9 from Single-Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Breast Cancer in <i>brca1</i> Mutation Carriers